{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:05:26Z","timestamp":1789639526328,"version":"4.0.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Antiphospholipid syndrome (APS) is a rare heterogenous autoimmune disorder with severe life-threatening complications shown during pregnancy. In this analysis, we aimed to systematically compare the pregnancy outcomes (both maternal and fetal) in patients with APS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Web of Science, Google Scholar, Medicus, Cochrane Central, Embase, and Medline were searched for relevant English publications. The main inclusion criteria were based on studies that compared pregnancy outcomes in patients with APS vs a control group. Statistical analysis was carried out by the RevMan software version 5.3. This analysis involved dichotomous data, and risk ratios (RR) with 95% confidence intervals (CIs) were used to represent the analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eight studies consisting of a total number of 212,954 participants were included. Seven hundred seventy participants were pregnant women with APS and 212,184 participants were assigned to the control group. Pregnancy-induced hypertension was significantly higher in women with APS (RR: 1.81, 95% CI: 1.33 \u2013 2.45; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0002). The risks of fetal loss (RR: 1.33, 95% CI: 1.00\u20131.76; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.05), abortion (RR: 2.42, 95% CI: 1.46\u20134.01; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0006), thrombosis (RR: 2.83, 95% CI: 1.47\u20135.44; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.002), and preterm delivery (RR: 1.89, 95% CI: 1.52\u20132.35; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.00001) were also significantly higher in women with APS. However, placental abruption (RR: 1.35, 95% CI: 0.78\u20132.34; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.29) and pulmonary embolism were not significantly different (RR: 1.47, 95% CI: 0.11\u201319.20; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.77). The risk of neonatal mortality (RR: 3.95, 95% CI: 1.98\u20137.86; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0001), infants small for gestational age (RR: 1.38, 95% CI: 1.04\u20131.82; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.02), premature infants (RR: 1.86, 95% CI: 1.52\u20132.28; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0001), and infants who were admitted to neonatal intensive care unit (RR: 3.35, 95% CI: 2.29\u20134.89; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.00001) were also significantly higher in women with APS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This analysis showed APS to be associated with significantly worse pregnancy outcomes when compared to the control group. A significantly higher risk of maternal and fetal complications was observed in this category of patients. Therefore, intense care should be given to pregnant women with APS to monitor unwanted outcomes and allow a successful pregnancy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000015733","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T10:44:01Z","timestamp":1558003441000},"page":"e15733","source":"Crossref","is-referenced-by-count":51,"title":["Pregnancy outcomes in patients with primary antiphospholipid syndrome"],"prefix":"10.1097","volume":"98","author":[{"given":"Liping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"277","DOI":"10.23736\/S0392-0488.18.06152-7","article-title":"Antiphospholipid syndrome and pregnancy","volume":"154","author":"Satta","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.autrev.2018.03.018","article-title":"Antiphospholipid syndrome: an update on risk factors for pregnancy outcome","volume":"17","author":"De Carolis","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaut.2017.02.009","article-title":"Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016","volume":"79","author":"Bundhun","year":"2017","journal-title":"J Autoimmun"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12884-018-1850-x","article-title":"Arterial\/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: a systematic review and meta-analysis","volume":"18","author":"Bundhun","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1515\/jpme.1997.25.2.192","article-title":"Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy","volume":"25","author":"Botet","year":"1997","journal-title":"J Perinat Med"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0961203314565689","article-title":"Vascular- and pregnancy-related outcomes in patients with systemic lupus erythematosus with positive antiphospholipid profile and thrombocytopenia","volume":"24","author":"Haddad","year":"2015","journal-title":"Lupus"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/rheumatology\/kei159","article-title":"The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and\/or the antiphospholipid syndrome","volume":"45","author":"Le Thi Huong","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10067-015-3050-7","article-title":"Pregnancy outcome of 126 anti-SSA\/Ro-positive patients during the past 24 years--a retrospective cohort study","volume":"34","author":"Luo","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jri.2012.02.004","article-title":"Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels","volume":"94","author":"Mekinian","year":"2012","journal-title":"J Reprod Immunol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3233\/NPM-1370113","article-title":"Outcomes of pregnancies in women with suspected antiphospholipid syndrome","volume":"6","author":"Nili","year":"2013","journal-title":"J Neonatal Perinatal Med"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.3109\/14767058.2016.1152254","article-title":"Maternal and fetal outcome in women with antiphospholipid syndrome: a three-year observational study","volume":"29","author":"Rezk","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/ard.2006.061671","article-title":"Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetalcharacteristics of 15 cases","volume":"66","author":"G\u00f3mez-Puerta","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"525.e1","DOI":"10.1016\/j.ajog.2017.01.026","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R17-20230914","first-page":"2025","article-title":"A study of 75 pregnancies in patients with antiphospholipid syndrome","volume":"28","author":"Huong","year":"2001","journal-title":"J Rheumatol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0961203317692432","article-title":"Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventionaltreatment: the influence of a triple positive antibody profile","volume":"26","author":"Latino","year":"2017","journal-title":"Lupus"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jri.2017.08.001","article-title":"Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: a multicenter study","volume":"122","author":"Deguchi","year":"2017","journal-title":"J Reprod Immunol"},{"key":"R20-20230914","first-page":"1","article-title":"Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials","volume":"5","author":"Lu","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201905170-00104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:18:19Z","timestamp":1694729899000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201905170-00104"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":20,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000015733","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}